Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 9/20 | 0.37 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765283 | 0.77 | CYP2A6 (0.43) | CYP2A6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL14197740 | 0.74 | CYP2A6 (0.57) | CYP2A6APPGAA | |
| SCHEMBL10000463 | 0.72 | NCEH1 (0.44) | ALDH1A1MAPT | |
| SCHEMBL29955990 | 0.72 | CA12 (0.53) | CYP2A6KDM4EALDH1A1GAA | |
| SCHEMBL16682553 | 0.71 | MAPT (0.39) | CYP2A6APPKDM4EALDH1A1MAPT | |
| SCHEMBL24089837 | 0.71 | POLB (0.32) | APPKDM4EALDH1A1MAPT | |
| SCHEMBL25366847 | 0.70 | CYP2A6 (0.43) | CYP2A6ALDH1A1MAPTHPGD | |
| SCHEMBL6437793 | 0.69 | MEN1 (0.42) | GSTO1ALDH1A1HIF1A | |
| SCHEMBL30936758 | 0.68 | RIPK1 (0.40) | KDM4EALDH1A1GLAMAPT | |
| SCHEMBL3313756 | 0.68 | ALDH1A1 (0.40) | NR1D1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | MEDAREX, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | PDIA5, CD38, DUT | CYP2A6 2406/4885APP 4239/4885GSTO1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.